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background: More than 15 million women, many of reproductive age, were infected with human immunodeﬁciency virus (HIV) at the
end of 2007. As the HIV epidemic evolves, heterosexual intercourse is increasingly risky: the risk of infection in exposed young women is 4-
to 7-fold higher than in young men and nearly half a million newborns annually have HIV. This review aims to show the effect of contraceptive
choices on risk of HIV and on the course of disease in women with HIV.
methods: Relevant citations were selected by agreement between the authors after a search of MEDLINE using the terms HIV/AIDS
and contraception.
results: Risk of transmission of HIV varies from 1 in 200 to 1 in 10 000 coital incidents, depending in part on the integrity of the vaginal
epithelium. Consistent use of male condoms has been proven to reduce horizontal transmission of HIV by 80% among HIV-serodiscordant
couples. Hormonal contraception may increase the risk of HIV acquisition in high-risk women such as commercial sex workers, but not in
women at low risk of HIV. While hormonal contraception did not affect progression of disease in two cohort studies involving 370 women, in
a randomized trial among women not receiving antiretroviral medication, clinical disease accelerated in the oral contraception group (13.2/
100 woman-years) compared with the copper intrauterine devices group (8.6/100 woman-years; hazard ratio, 1.5; 95% conﬁdence interval,
1.04–2.1). Hormonal contraception does not interfere with antiviral drug effectiveness.
conclusions: All the available reversible contraceptive methods can generally be used by women at risk of HIV infection and by
HIV-infected women. Further studies are needed to investigate the safety and efﬁciency of hormonal contraception in women living with
HIV/AIDS.
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Background
The global human immunodeﬁciency virus (HIV) pandemic is increas-
ingly becoming a burden of the female population. At the end of 2007,
an estimated 15.4 million women were infected with HIV, most of
them being of fertile age (www.data.unaids.org). Importantly, young
women aged 15–24 have a 4- to 7-fold increased risk of becoming
infected with HIV, when compared with young men of the same age
(Simon et al., 2006). Moreover, an estimated 420 000 HIV-infected
children are born annually (who.int), and most of these infections
could and should be prevented.
The demographics and routes of infection vary according to the
phase of the HIV epidemic (Beyrer, 2007). As the phase advances,
heterosexual intercourse becomes an increasingly important route
of transmission (Simon et al., 2006). In sub-Saharan Africa, the vast
majority of cases of HIV transmission (c. 90%) are estimated to
occur via heterosexual intercourse (data.unaids.org).
In the light of vastly different cultures and contraceptive practices,
several methods of providing protection from both unintended preg-
nancy and sexually transmitted disease (STD) should ideally be avail-
able. According to the current consensus of opinion, HIV-infected
women and women at risk of HIV infection can use all available
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However, male condoms represent the only contraceptive method
effective in prevention of horizontal transmission of HIV (Weller and
Davis-Beaty, 2002). Given the expanding epidemic and the great
number of HIV-infected children born, additional contraceptive
methods are needed, preferably linked to methods reducing the risk
of HIV transmission.
The aim of the present article is to review current knowledge on
heterosexual transmission of HIV and the factors affecting the risk of
transmission of HIV. We will focus particularly on the effect of contra-
ceptive choices among women at risk of HIV infection and those living
with HIV/AIDS. As a highly relevant public health issue, the topic has
been reviewed previously (Howe et al., 1994; Stephenson, 1998;
Mitchell and Stephens, 2004; Morrison et al., 2005; Baeten et al.,
2007a).
Materials and Methods
The citations for the present review were identiﬁed via MEDLINE and
PubMed searches using the passwords of HIV, AIDS, transmission, risk
factors and contraception. In addition, personal knowledge of the ﬁeld
and cross referencing was used. The citations were used only following
agreement between the authors.
HIV transmission during heterosexual
intercourse
Transmission of HIV during heterosexual intercourse is inefﬁcient, and has
been estimated to occur at a rate of 1/200–10 000 (Shattock and Moore,
2003). The results of several prospective cohort studies performed among
HIV-serodiscordant couples suggest that the risk of male-to-female trans-
mission may be higher than that of female-to-male transmission (De Vin-
cenzi, 1994; Padian et al., 1997). The estimates of increased risk have
varied from 2- to 8-fold (Padian et al., 1997). However, there are also
studies indicating a similar risk of HIV acquisition regardless of the
gender of the HIV-seropositive partner (Deschamps et al., 1996; Quinn
et al., 2000; Castilla et al., 2005). Explanations for the potentially increased
susceptibility of women include female anatomy, longer exposure, as
sperm remains in the vagina, and presence of another STD.
The molecular and cellular mechanisms of heterosexual transmission of
HIV have been recently reviewed by Shattock and Moore (2003) and by
Gupta and Klasse (2006). In brief, infectious HIV must cross the vaginal
or cervical epithelium in order to reach its main cellular targets,
CD4-expressing lymphocytes, and dendritic cells. If HIV can cross intact
epithelium, and if so, then how, remains enigmatic—infection, transcytosis
and transmigration via infected donor cells have been proposed (Shattock
and Moore, 2003). In order for HIV to infect its cellular targets, both CD4
receptors and their co-receptors (either CCR-5 or CXCR4) are needed
on the surface of the lymphocytes and dendritic cells.
Hence, healthy vaginal epithelium is vital in order to diminish the risk of
HIV transmission, and all factors disrupting the epithelium—such as phys-
ical or infectious ulceration or inﬂammatory conditions, such as those
associated with STDs—result in increased susceptibility to HIV. Tables I
and II summarize various factors associated with an increased risk of het-
erosexual transmission of HIV.
Risk factors of HIV acquisition in women
When discussing the risk of HIV transmission in heterosexual intercourse,
two factors—infectiousness of the infected partner and susceptibility of
the uninfected partner—need to be considered (Padian, 1998; Galvin
and Cohen, 2004).
Factors affecting infectiousness
The circulating HIV load of the infected partner is a major predictor of the
risk of heterosexual transmission. In a prospective cohort study performed
in Uganda (Quinn et al., 2000), the risk of HIV acquisition increased more
than 10-fold as the circulating HIV-1 RNA load increased from ,3500 to
.50 000 copies/ml. No transmissions occurred during the follow-up
period of 2.5 years if the circulating HIV-1 RNA load was below
1500 copies/ml (Quinn et al., 2000). The circulating HIV-1 RNA load is
themostimportantpredictorofHIVsheddingintocervicovaginalsecretions
or seminal ﬂuid (Gupta et al., 1997; Debiaggi et al., 2001). Thus, a high HIV
load in the blood is likely to be reﬂected in increased levels of HIV in cervi-
covaginal secretions or seminal ﬂuid. However, the genital pool of HIV is
thought to be somewhat separate from the systemic one, and occasional
genital shedding of HIV is seen even among subjects receiving highly active
antiretroviral medication resulting in undetectable circulating HIV RNA
levels (Debiaggi et al., 2001; Heikinheimo et al., 2006).
Along with the effect of the circulating HIV load, the stage of HIV infec-
tion has an effect of the risk of transmission. Thus, during the course of
HIV/AIDS, infectiousness follows a U-shaped curve. The risk of HIV trans-
mission is at its highest during early infection (at the time of viraemia) as
well as during the ﬁnal stages of infection (Wawer et al., 2005). In compari-
son with prevalent infections, the relative risk of HIV transmission during
the acute phase of infection has been found to be increased more than
7-fold (Wawer et al., 2005). Analogously, the level of HIV RNA in
serum and in seminal ﬂuid is at its highest among antibody-negative men
during the ﬁrst month following infection (Pilcher et al., 2007). Accordingly,
the risk of heterosexual transmission is strongly diminished (80%) among
serodiscordant couples when the HIV-infected partner is receiving highly
active antiretroviral therapy (HAART) (Castilla et al., 2005).
Randomized controlled trials performed in Africa have shown that male
circumcision lowers the risk of acquiring HIV infection among men (Auvert
et al., 2005; Bailey et al., 2007; Gray et al., 2007; Newell and Ba ¨rnighausen,
2007). However, the impact of male circumcision on the risk of
male-to-female transmission of HIV is less clear. Circumcision of the
male partner has been associated with a lower risk of HIV transmission
in some studies (Kapiga et al., 1998; Gray et al., 2000). However, in a
recent prospective study involving evaluation of the safety of hormonal
contraception in African women, the protective effect of male circumci-
sion on the risk of HIV infection among women disappeared following
Table I Factors associated with increased risk of HIV
acquisition in women
Partner/male-associated factors
Advanced stage of HIV infection (Saracco et al., 1993; DeVicenzi, 1994;
Quinn et al., 2000)
High circulating HIV load (Quinn et al., 2000)
Uncircumcised partner (Kapiga et al., 1998)
Female-associated factors
Young age at coital debut (Pettifor et al., 2004)
Age ,25 years (Laga et al., 1993; Morrison et al., 2007)
Age .45 years (De Vincenzi, 1994)
 4 sex partners (Kapiga et al., 1998)
Practice of anal sex (De Vincenzi, 1994)
Not living with partner (Morrison et al., 2007)
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circumcision is promoted as in important means of HIV prevention
(http://whqlibdoc.who.int, 2007).
Factors affecting susceptibility
Concomitant infection with other STDs, especially those resulting in
ulcerative genital lesions, has emerged as a highly signiﬁcant risk factor
of HIV transmission (Table II, Galvin and Cohen, 2004). Besides physical
disruption of the epithelium, cervical infections increase the number of
CD4-positive lymphocytes and dendritic cells in the cervix (Pudney
et al., 2005), thereby increasing susceptibility to HIV. Thus, the prevalence
of STDs has a major impact on the rapidity of spread and routes of HIV
transmission in a given society.
Of the various STDs, co-infection with herpes simplex virus-2 seems to
have the most pronounced effect on the risk of HIV transmission in het-
erosexual intercourse (Brown et al., 2007). Thus, suppression of HSV-2
with acyclovir prophylaxis might be effective in reducing the rate of HIV
transmission. However, in a recent randomized study, prophylaxis with
acyclovir had no effect on the incidence of HIV infection among HIV-1-
seronegative and HSV-2-positive Tanzanian women (Watson-Jones
et al., 2008).
In a recent meta-analysis of 68 epidemiological studies performed in
sub-Saharan Africa, a history of multi-partner sex, paid sex and STDs
were risk factors of HIV infection in women. The odds ratios (ORs)
(with 95% conﬁdence intervals) for various risk factors in women were
3.64 (2.87–4.62) for  3 versus 0–2 lifetime sex partners, 2.29 (1.45–
3.62) for having ever been paid for sex and 2.39 (2.01–2.84) for a
history of STD. The highest OR, of 4.6 (2.85–7.47), was associated
with HSV-2 infection (Chen et al., 2007). The risk factors and the magni-
tude of risk persisted both in low- and high-risk populations, and in popu-
lations with early and advanced states of the HIV epidemic (Chen et al.,
2007).
Thus, the optimal contraceptive strategy and service provision is aimed
both at reducing the factors known to facilitate heterosexual transmission
of HIV—particularly STDs—as well as minimizing unintended pregnancy.
Promoting the use of dual contraception by concomitant use of
condoms and additional contraception is likely to be demanding in many
parts of the world.
Barrier methods are effective in reducing the
risk of HIV transmission
Male condoms
As of today, male condoms are the only means proven to signiﬁcantly
reduce the risk of HIV transmission in heterosexual intercourse (Cates,
2005). According to a recent Cochrane review, consistent use of male
condoms results in 80% reduction in the risk of HIV transmission among
HIV-serodiscordant couples (Weller and Davis-Beaty, 2002). Of the
studies including only HIV-negative women and their HIV-infected men,
the efﬁcacy of consistent condom use in prevention of HIV transmission
was remarkable, with a relative risk varying from 0.1 to 0.2 (Saracco
et al., 1993; Musicco et al., 1994). Morover, during the follow-up period
of nearly 2 years, De Vincenzi (1994) reported no seroconversions
among the 124 couples consistently using condoms.
It is also noteworthy that a reduced risk of HIV transmission is associ-
ated only with consistent but not with occasional condom use. In fact,
occasional condom use has been associated with an increased risk of
HIV transmission in some studies (Saracco et al., 1993; Musicco et al.,
1994). However, a major challenge in evaluation of condom use is that
the data is self-reported and therefore, in many cases, its reliability may
be questionable. This is related especially to consistency of use.
Many of the studies involving assessment of the efﬁcacy of male
condoms in prevention of HIV transmission were carried out before
the era of effective antiretroviral medication. The use of zidovudine
monotherapy by the HIV-infected male partner has been reported to
halve the risk of HIV transmission (Musicco et al., 1994), and during
the use of current combination therapy the rate of HIV transmission
was even lower (Castilla et al., 2005). No HIV transmissions were
reported among serodiscordant couples if the HIV-infected partner
received HAART and a condom was used every time the couple had
sex (Castilla et al., 2005).
Given the efﬁcacy of consistent use of male condoms in the prevention
of HIV transmission in heterosexual intercourse, it is disappointing to note
the low prevalence of condom use reported in many studies. In addition,
the rate of reported condom use varies greatly in studies performed in
different continents. The lowest rate of condom use is reported in
studies carried out in Africa. Only 10% or less of African women
...............................................................................................................................................................................................
Table II Inﬂammatory conditions associated with increased risk of HIV acquisition in women
Risk factor Increase in the
risk of HIV
transmission
References
Cervical ectopy 4.9 Plourde et al. (1994)
Pelvic inﬂammatory disease 6.3 Plourde et al. (1994)
Ulcerative genital infection 2.9–3.0 DeVicenzi (1994), Martin et al. (1998), Kiddugavu et al. (2003)
Speciﬁc diagnosis of
Bacterial vaginosis 1.4–2.8 Martin et al. (1998), Kleinschmidt et al. (2007)
Vaginal candidiasis 2–3.3 Kapiga et al. (1998), Martin et al. (1998)
Chlamydia trachomatis 1.3–3.6 Laga et al. (1993), Martin et al. (1998)
Neisseria gonorrhoea 1.8–5.2 Laga et al. (1993), Kapiga et al. (1998), Martin et al. (1998), Kleinschmidt et al. (2007)
Herpes simplex virus-2 (seroprevalent) 2.8–4.4 Baeten et al. (2007b), Brown et al. (2007)
HSV-2 (seroincident) 4.6–8.6 Brown et al. (2007)
Treponema pallidum 1.6–5.8 Ungchusak et al. (1996), Martin et al. (1998)
Trichomonas vaginalis 1.2–4.8 Laga et al. (1993), Martin et al. (1998), Kleinschmidt et al. (2007)
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traception among women at risk of HIV (Tables III and IV) reported the
dual use of hormonal contraception and condoms (Kiddugavu et al.,
2003; Morrison et al., 2007; Myer et al., 2007). Similarly, condom use at
any time was reported by ,10% of HIV-infected women participating in
a study in which the use of a Cu-releasing intrauterine device (Cu-IUDs)
was assessed (Richardson et al., 1999).
The rate of consistent condom use is also relatively low in studies
performed in developed countries. In an early Italian study, only 48% of
serodiscordant couples reported consistent condom use (De Vincenzi,
1994). Similarly, inconsistent condom use was common (45%) among
HIV-serodiscordant Californian couples, and correlated with low socioe-
conomic status, African–American ethnicity and practice of anal sex
(Buchaz et al., 2001).
...............................................................................................................................................................................................
Table III Prospective cohort studies involving assessment of the effect of oral contraceptives on the risk of HIV acquisition
among HIV-negative women
References Nos Study
site
Population
studied
Incidence of HIV/100
woman-years
Risk [95% CI] of HIV
acquisition; OCs
versus non-hormonal
methods
Kapiga et al.
(1998)
1211 ever users of OCs versus
159 other methods
Tanzania Family planning
clinic attendees
3.5 in ever users of OCs versus 2.6 in
non-users
1.01 (0.45–2.28)
Kiddugavu
et al. (2003)
421 OC users among 5117
women followed
Uganda Community-based,
women aged
15–49
2.5 users of OCs versus 1.5 in users of
non-hormonal contraception
1.12 [0.48–2.56]
Morrison et al.
(2007)
1583 COC users versus 1412
users of non-hormonal
contraception
Uganda
and
Zimbabwe
Family planning
clinic attendees
2.59 in users of COCs versus 2.55 in
users of non-hormonal contraception
0.99 [0.69–1.42]
Myer et al.
(2007)
94 COC users versus 3304
non-hormonal method
South
Africa
Women attending
cervical screening
trial
1.80 in users of COCs versus 2.16 in
users of non-hormonal contraception
0.65 [0.16–2.66]
Baeten et al.
(2007b)
a
269 OC users versus 568
users of non-hormonal
methods
Kenya Commercial sex
workers
11.88 in users of OCs versus 6.49 in
users of non-hormonal contraception
1.46 [1.00–2.13]
aOf the on-going studies that have been reported in several publications (e.g. Martin et al., 1998 Lavreys et al., 2004a; Baeten et al., 2007b), only the latest results are included.
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Table IV Prospective cohort studies involving assessment of the effect of injectable contraceptives on the risk of HIV
acquisition
References Nos Study site Population studied Incidence of HIV/100
woman-years
Risk [95% CI] of HIV
acquisition versus
non-hormonal method
Kapiga et al.
(1998)
129 DMPA users versus 1241
other methods
Tanzania Family planning clinic
attendees
0.9 in DMPA users versus 4.1 in
non-users
DMPA use 0.30 [0.07–1.26]
Kiddugavu et al.
(2003)
635 users of injectable
contraception versus 4267
non-hormonal method
Uganda Community-based,
women aged 15–49
2.2 in sometime users of DMPA
versus 1.5 in non-users
Injectable contraception use
0.84 [0.41–1.72]
Morrison et al.
(2007)
1536 users of DMPA versus
1412 users of non-hormonal
contraception
Uganda and
Zimbabwe
Family planning clinic
attendees
3.11 in users of DMPA versus 2.55
in users of non-hormonal
contraception
DMPA use 1.25 [0.89–1.78]
Myer et al.
(2007)
603 DMPA users, 199
NET-EN users versus 3304
users of non-hormonal
method
South Africa Women attending
cervical screening trial
2.62 in users of DMPA, 2.16 in
NET-EN users versus 2.16 in users
of non-hormonal contraception
DMPA use 0.96 [0.58–1.59],
NET-EN 0.79 [0.31–2.02]
Baeten et al.,
2007b
a
369 DMPA users versus 568
users of non-hormonal
method
Kenya Commercial sex
workers
14.13 in users of DMPA versus 6.49
in users of non-hormonal
contraception
DMPA use 1.73 [1.28–2.34]
Kleinschmidt
et al., 2007
108 DMPA users, 192
NET-EN users versus 251
non-hormonal method
South Africa Family planning clinic
attendees
1.1 in users of DMPA versus 7.5 in
users of NET-EN versus 4.4 in users
of non-hormonal contraception
DMPA use 0.46 [0.06–3.79],
NET-EN 1.76 [0.64–4.84]
aOf the on-going studies that have been reported in several publications (e.g. Martin et al., 1998, Lavreys et al., 2004a; Baeten et al., 2007b), only the latest results are included. DMPA,
depot medroxyprogesterone acetate; NET-EN, norethindrone enanthate.
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In addition to male condoms, female condoms have been developed. In a
prospective study with one-third of the subjects being fully compliant with
the method, the contraceptive efﬁcacy of female condom was similar to
that of other barrier methods (Farr et al., 1994). In an other prospective
study, performed among women at high risk of STDs, ,10% the women
used female condom as their only barrier method and of those trying the
method, one-third used it only once or twice (Macaluso et al., 2000).
However, the use of female condoms may increase the use of condoms
in general (Macaluso et al., 2000). So far, the efﬁcacy of female condoms
in reducing the risk of HIV transmission remains to be shown (Minnis and
Padian, 2005).
Because the uterine cervix has a high number of dendritic cells and may
constitute the main port of HIV entry in heterosexual transmission of HIV
(Pudney et al., 2005), the use of diaphragms has been studied as regards
the prevention of HIV transmission. However, the use of a diaphragm in
addition to screening, counselling and provision of male condoms did
not have an effect on the rate of HIV transmission among HIV-
seronegative Southern African women recruited from community- and
clinic-based organizations (Padian et al., 2007). However, the reported
use of male condoms was signiﬁcantly lower among the women random-
ized to use of a diaphragm (Padian et al., 2007).
Spermicides
Nonoxynol-9 is a detergent thatfunctions as a spermicide and antimicrobial
agent, and it has been used widely as a topical contraceptive. As
nonoxynol-9 has anti-HIV activity in vitro, its use during sexual intercourse
was expected to reduce the transmission of HIV. However, in large ran-
domized, placebo-controlled trials performed among female sex workers
in Africa and Asia, the use of nonoxynol-9 did not lower the risk of HIV
acquisition (Roddy et al., 1998; Richardson et al., 2001; van Damme
et al., 2002). Moreover, an increased incidence of HIV—most likely due
to an increase in vaginal erosion—was seen among women using several
daily applications of nonoxynol-9 (van Damme et al., 2002). Nonoxynol-9
is therefore no longer studied in HIV prevention programmes.
Microbicides
Microbicides are products in the form of a gel, tablet, ﬁlm or sponge that
need to be introduced into the vagina before sexual intercourse. Microbi-
cides are being extensively studied in Africa and other regions as regards
the development of female-controlled methods of HIV prevention (Stone
and Jiang, 2006). Unfortunately, the results reported so far have been dis-
appointing. In a recently published, prematurely terminated trial, the use of
HIV-entry inhibitor cellulose sulphate did not prevent, but might have
increased the risk of HIV transmission (van Damme et al., 2008). A
phase 3 trial on the safety and efﬁcacy of Carraguard, a seaweed-based
candidate microbicide was completed (www.popcouncil.org). Although
Carraguard proved to be safe, this trial did not demonstrate that it was
superior to placebo in HIV prevention. The ﬁndings suggested that use
of the products remained low throughout the trial. This may mean that
adherence to methods that require coitus-dependent action will be less
successful in HIV prevention. However, both basic and applied research
on microbides continues and several microbicide trials are on-going
(www.ipm-microbicides.org).
Contraception in women at risk of HIV
infection
Oral contraceptives and the risk of HIV infection
As more than 100 million women use hormonal contraception globally
(www.un.org), the potential effects of hormonal contraception on suscep-
tibility to HIV is of utmost importance. Whether the use of hormonal
contraception has an effect on the risk of HIV acquisition has been a
matter of debate. There are multiple mechanisms by which the use of hor-
monal contraceptives might increase a woman’s susceptibility to HIV
(Baeten et al., 2007a). Oral contraceptives (OCs) increase cervical ectopy
(Critchlow et al., 1995), and cervical ectopy has been linked to increased
susceptibility to STDs, including HIV in some (Louv et al., 1989; Plourde
et al., 1994), but not in all studies (Morrison et al., 2004). However,
results of prospective studies have revealed an increased incidence of
STDs in women using hormonal contraception (Baeten et al., 2001; Mor-
rison et al., 2004). In addition, sex steroids have been reported to increase
expression of the HIV-1 co-receptor CCR5 in cervical CD4þ lympho-
cytes (Prakash et al., 2002) and up-regulate HIV-1 gene expression
(Furth et al., 1990).
The fear of increased susceptibility to HIV during the use of hormonal
contraception was further fuelled by results published by Marx et al.
(1996). In the primate model of HIV infection, i.e. simian immunodeﬁ-
ciency virus (SIV) infection, vaginal transmission of SIV was markedly
enhanced during the use of progesterone-releasing implants (Marx et al.,
1996). The increased transmission of SIV was associated with marked thin-
ning of the vaginal epithelium in progesterone-treated primates (Marx
et al., 1996), most likely due to suppression of ovarian function and resul-
tant hypoestrogenism. Thus, vaginal estrogen application normalized the
epithelium and inhibited the transmission of SIV in a primate model (Li
and Short, 2002; Smith et al., 2004). In addition, progestin-only contracep-
tives—levonorgestrel-releasing implants and depot medroxyprogesterone
acetate (DMPA)—designed for women, result in progestin levels, which
exceed those measured in women, and thinning of the vaginal epithelium
in primates (Hild-Petito et al., 1998). However, no thinning of the vaginal
epithelium has been reported in women during the use of DMPA (Mauck
et al., 1999; Bahamondes et al., 2000).
The potential effect of OCs on the risk of HIV acquisition has been eval-
uated in both cross-sectional and prospective clinical studies. The number
of studies that have involved assessment of contraception among the risk
factors of HIV acquisition exceed 50 (Baeten et al., 2007a, Bulterys et al.,
2007). These studies have been performed among different populations,
mainly in developing countries. In addition, most of the studies were
carried out before the era of antiretroviral medication. Thus, many of
the early studies and their conclusions have been criticized for reasons
such as low number of hormonal contraception users, poor comparability
of different study groups, insufﬁcient follow-up and poor generalizability of
results (Morrison et al., 2005).
The ﬁrst prospective studies involving assessment of the risk of HIV
infection in women in relation to sexual behaviour, including the use of
OCs, were published in the early 1990s. In the early studies performed
in Africa, the risk factors of HIV acquisition began to surface—young
age, genital ulceration, cervical ectopy, STDs and inconsistent use of
condoms—and these were later conﬁrmed in large studies (Plummer
et al., 1991; Laga et al., 1993; Bulterys et al., 1994; Plourde et al.,
1994). Use of OCs was a risk factor of HIV acquisition among high-risk
women (Plummer et al., 1991), but not among women at low risk (Bul-
terys et al., 1994).
In the only prospective study performed in Europe, no HIV infections
occurred during the follow-up period of 14 months among the 22 serone-
gative women who used OCs and were in monogamous relationships with
HIV-infected men (Saracco et al., 1993). In the study, performed during
the era of zidovudine monotherapy, the overall incidence of HIV infection
was 3.6/100 woman-years (Saracco et al., 1993).
The largest prospective cohort studies involving assessment of the
effects of OCs on the risk of HIV acquisition, all performed in Africa,
are summarized in Table III. All these studies were speciﬁcally designed
to assess the effects of hormonal contraception on the risk of HIV acqui-
sition, with adequate numbers of women and follow-up procedures.
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the highest incidence being noted among Kenyan sex workers (Baeten
et al., 2007b). Similarly, considerable variation between different study
sites and countries has been reported. For example, in the study by Mor-
rison et al. (2007), the incidence of HIV infection was 1.6/100 woman-
years in Uganda, whereas it was 4.1 in Zimbabwe. Thus, the risk of HIV
acquisition varies greatly among different populations and locations.
Based on the results of the studies summarized (Table III) it may be con-
cluded that the use of OCs seems to be associated with an increased risk
of HIV acquisition among women at high risk (such as sex workers). More-
over, in a continuing study performed among sex workers in Mombasa
(Martin et al., 1998; Lavreys et al., 2004b; Baeten et al., 2007b), women
acquiring HIV were infected with multiple variants of the virus (Long
et al., 2000). In a subsequent prospective study, genital tract infections
and the use of hormonal contraception speciﬁcally increased the risk of
acquiring multiple variants of HIV among Kenyan sex workers (Sagar
et al., 2004). However, among other African women, no increased risk
of HIV has been observed during the use of OCs. Thus, the background
risks, and not the potential effect of OCs, seem to be the major determi-
nants of the risk of HIV acquisition.
Injectable contraceptives and the risk of HIV infection
The ﬁrst studies concerned with assessment of the use of injectable con-
traceptives, performed among female prostitutes in Thailand, revealed an
increased risk of HIV acquisition. The risk of HIV associated with the use of
injectable contraceptives was as high as 3.4/100 woman-years (95% CI
1.2–13.2). The incidence of HIV was also high—9.2/100 woman-years
(Rehle et al., 1992; Ungchusak et al., 1996). Similary, a recent analysis per-
formed among young (15–24 years old) women in four African countries
concluded that the use of DMPA, but not that of OCs, increased signiﬁ-
cantly the risk of HIV seropositivity (Leclerc et al., 2008). Yet, the
overall risk associated with the use of DMPA was small, i.e. 1.34 (95%
CI 1.1–1.6) (Leclerc et al., 2008).
However, cohort studies assessing the safety of injectable contracep-
tives, carried out in Africa among family planning clinic attendees, or
community-based cohorts, have not conﬁrmed the elevated risk
(Table IV). As with OCs, the risk of HIV acquisition seems to be increased
during the use of injectable contraception only among women at high risk
(Ungchusak et al., 1996; Baeten et al., 2007b).
Thus an increased risk of HIV acquisition associated with the use of hor-
monal contraceptives has been demonstrated only among commercial sex
workers, and potentially among young women. As the various confounding
factors (such as demographic, exposure or biologic) have been controlled
for (Martin et al., 1998; Baeten et al., 2007b) this suggests the existence of
still an uncontrollable factor, explaining the increased risk of HIV-infection
among these high-risk women. However, among African women in general
the use of hormonal contraception does not seem to convey an increased
risk of HIV acquisition.
When comparing different studies, considerable variation in the rates of
lost to follow-up as well as in the prevalence of STDs has been noted. In
the studies summarized in Tables III and IV, the number of women lost to
follow-up has varied from 8% (Kleinschmidt et al., 2007; Morrison et al.,
2007) to 45% (Kapiga et al., 1998). The prevalence of STDs at baseline
was also highly variable. For example, the prevalence of Trichomonas vagi-
nalis varied from 3% (Morrison et al., 2007) to 13% (Kapiga et al., 1998),
whereas that of Neisseria gonorrhoea was reported among 2–7% of the
women followed (Kapiga et al., 1998; Martin et al., 1998; Kleinschmidt
et al., 2007; Morrison et al., 2007).
Do concomitant STDs modify the risk of HIV acquisition?
As STDs signiﬁcantly increase women’s susceptibility to HIV, evaluation of
the potential additive effects of STDs and hormonal contraception on the
risk of HIV infection is important. In one of the largest studies (Morrison
et al., 2007), the presence of chlamydia, gonorrhoea, trichomoniasis, bac-
terial vaginosis or yeast infection did not have an effect on the risk of HIV
acquisition among women using hormonal contraception.
However, a signiﬁcantly increased risk of HIV acquisition was seen
among women using hormonal contraception (both OCs and DMPA)
and who were HSV-2-negative at baseline (Morrison et al., 2007). The
risk was not associated with HSV-2 seroconversion, and no such increase
was noted among HSV-2-seropositive women (Morrison et al., 2007).
Given the highly increased susceptibility of HSV-2-positive women to
HIV (Table II), the increased incidence of HIV among HSV-2-negative
women is puzzling. In contrast to the above-mentioned results obtained
among women attending family planning clinics, HSV-2 serostatus did
not modify the risk of HIV acquisition among commercial sex workers
who used hormonal contraception (Baeten et al., 2007b). However,
relationships between hormonal contraception, HSV-2 status and the
risk of HIV infection merit further studies.
The use of IUDs in women at risk of HIV infection
Traditionally, the use of IUDs among women at risk of HIV infection has
been viewed cautiously (WHO, 2000). As the number of women using
IUDs globally exceeds 130 million (www.un.org), with twice as high a
prevalence of IUD use in less-developed countries, the issue of IUD
safety is of vital importance.
The two prospective studies evaluating the risk of HIV acquisition during
use of an IUD are summarized in Table V. No increased risk of HIV has
been reported. Given the high rate of global IUD use, the small number
of studies is surprising. This may partly be a result of the fact that only a
small proportion of women use IUDs in sub-Saharan Africa, whereas
Asian countries (such as China) constitute the most important areas of
global IUD use (d’Arcangues, 2007). Until recently, women were con-
sidered to be at a relatively low risk of HIV infection in most parts of
China (data.unaids.org).
Thus, the available data suggest that use of a Cu-IUD does not increase
the risk of HIV acquisition (Table V). Therefore, in 2004, the WHO
...............................................................................................................................................................................................
Table V Prospective cohort studies involving assessment of the effect of intrauterine devices on the risk of HIV acquisition
References Nos Study site Population
studied
Incidence of HIV/100
woman-years
Risk [95% CI] of HIV
acquisition versus other
methods
Martin et al. (1998) 23 IUD users, 756 other
methods
Kenya Commercial sex
workers
Data not available Cu-IUD use 1.2 [0.4–3.9]
Kapiga et al. (1998) 162 IUD users, 1208 other
methods
Tanzania Family planning
clinic attendees
2.7 in IUD users versus 3.4
in non-users
Cu-IUD use 0.80 [0.38–1.69]
170 Heikinheimo and La ¨hteenma ¨kireclassiﬁed the use of both Cu-IUDs and the levonorgestrel-releasing
intrauterine system (LNG-IUS) to category 2 (‘generally use the
method’) for women at increased risk of HIV infection, and HIV-infected
women (http://www.who.int/reproductive-health/publications/mec/
mec.pdf).
Contraception in women living with HIV/
AIDS
Safety and efﬁcacy of hormonal contraception
The safety of hormonal contraception among HIV-1-infected women has
been assessed in two prospective cohort studies (Cejtin et al., 2003;
Richardson et al., 2007). In the study by Richardson et al. (2007), a
cohort of 193 postpartum Kenyan women, of whom 44% used hormonal
contraception (either DMPA or OCs), were followed-up for 2 years. No
differences in HIV RNA load, absolute levels or decline of CD4 lympho-
cyte levels were noted (Richardson et al., 2007). Similarly, in the
Women’s Interagency HIV Study, performed in the USA, the use of hor-
monal contraception was not associated with changes in circulating HIV
RNA levels, whereas minor increases in the levels of CD4 lymphocytes
were seen (Cejtin et al., 2003).
Only in one randomized study has the efﬁcacy and safety of OCs versus
IUDs among HIV-infected women been assessed (Stringer et al., 2007).
Nearly 600 HIV-infected Zairean women were randomized to hormonal
contraception (DMPA or OCs) versus Cu-IUD arms following delivery.
The women did not receive antiretroviral medication (Stringer et al.,
2007). During the minimum follow-up period of 2 years the women ran-
domized to hormonal contraception were 2.4-fold (95% CI 1.3–4.7) more
likely to become pregnant again (Stringer et al., 2007). Thus similarly as in
healthy women (Heikinheimo et al., 2008), intrauterine contraception was
more effective in preventing unintended pregnancy also in HIV-infected
women. Surprisingly, progression of HIV was more pronounced among
women randomized to hormonal contraception, and the risk of severe
immunodeﬁciency or death was increased 1.5-fold (95% CI 1.04–2.1)
(Stringer et al., 2007). The reasons for this are unclear, and conﬁrmatory
results are urgently needed.
Nevertheless, the use of hormonal contraception in HIV-infected
women is classiﬁed by the WHO as category 1 (‘use the method in any
circumstances’). As a result of potential pharmacokinetic interactions,
use of systemic hormonal contraceptives in women receiving antiretroviral
medication is listed in category 2 (http://www.who.int/reproductive-
health/publications/mec/mec.pdf).
Drug interactions
Use of antiretroviral medication may alter the metabolism of contraceptive
steroids (Mitchell and Stephens, 2004). However, evidence supporting
pharmacokinetic interactions is somewhat sporadic. Continuous use of
the antiretroviral drug nevirapine was associated with a lower area
under the concentration curve of ethinylestradiol and norethisterone fol-
lowing singe dose administration (Mildvan et al., 2002). Thus, when used
together with various antiretroviral drugs, administration of contraceptive
steroids might be susceptible to enhanced, unaltered or inhibited metab-
olism (El-Ibiary and Cocohoba, 2008). Similarly, contraceptive steroids
may have an effect on the metabolism of various antiretroviral drugs (Fro ¨h-
lich et al., 2004; Cohn et al., 2007). However, the clinical signiﬁcance of
these interactions is unclear and the interactions have not been studied
during the use of various combinations of antiretroviral medication (such
as HAART) currently in clinical use. Thus, concern over pharmacokinetic
interactions should not keep service providers from prescribing hormonal
contraceptives to women undergoing antiretroviral therapy.
Non-oral administration of contraceptive steroids to women using anti-
retroviral medication might be an efﬁcient means to minimize the risk of
pharmacokinetic interactions. However, this has been assessed only in
case of progestin-only contraceptives. In an open-label study, Cohn
et al. (2007) showed that serum levels of medroxyprogesterone acetate
(MPA) following DMPA injections were similar in women using and not
using antiretroviral medication. Ovulation is effectively suppressed follow-
ing DMPA use in women using antiretroviral medication (Cohn et al.,
2007; Watts et al., 2008), and unaltered levels of circulating HIV RNA
load and CD4 lymphocytes have been reported (Watts et al., 2008).
Changes, albeit clinically insigniﬁcant, have been seen in the levels of nelﬁ-
navir and nevirapine following the use of DMPA (Cohn et al., 2007).
Similarly, the effects of the LNG-IUS among HIV-infected women have
been reported to be similar to those seen in healthy women. The circulat-
ing levels of LNG were in the same range among women using and not
using antiretroviral therapy (Heikinheimo et al., 2006). Thus, non-oral
administration of progestin-only contraceptives is an important strategy
among women using antiretroviral medication. However, use of antiretro-
viral medication in combination with parenteral administration of com-
bined contraceptives, such as contraceptive vaginal ring or patch remain
to be studied.
Intrauterine devices
The safety of the Cu-IUD among women living with HIV/AIDS was ﬁrst
assessed in a prospective study performed in Kenya (Sinei et al., 1998;
Morrison et al., 2001). During the follow-up period of 2 years, no differ-
ences in overall complications or infectious morbidity emerged between
women infected and not infected with HIV. In addition, the status of the
HIV infection (as judged by CD4 lymphocyte levels) did not have an
effect on the risk of complications (Morrison et al., 2001). However, the
number of women lost to follow-up was high.
Similarly, in a recent randomized study performed in Zambia among
HIV-infected women, insertion of a Cu-IUD postpartum was effective
and safe (Stringer et al., 2007). In contrast to hormonal contraception,
the course of HIV infection was unaffected among women randomized
to the Cu-IUD group. Only one case of pelvic inﬂammatory disease,
resulting in a rate of 0.2/100 woman-years, was reported (Stringer
et al., 2007).
Use of the LNG-IUS in HIV-infected women has been assessed in one
case report (Cooling, 1999), a case series (Lehtovirta et al., 2007) and in
one clinical trial performed in Northern Europe (Heikinheimo et al., 2006).
In a prospective study the effects of the LNG-IUS were similar to those
observed in healthy women (Luukkainen and Toivonen, 1995)—menstrual
bleeding was reduced, ovarian activity maintained and the continuation
rate was high (Heikinheimo et al., 2006). Moreover, the LNG-IUS had
no effect on cervicovaginal shedding of HIV RNA (Heikinheimo et al.,
2006).
Thus, IUDs seem to be safe contraceptive options for HIV-infected
women with continuous access to medical care, and they are thus classi-
ﬁed as category 2 by the WHO. Due to suspected risk of pelvic infections,
initiation of intrauterine contraception in cases of AIDS remains in cat-
egory 3 (‘use of method not usually recommended unless other more
appropriate methods are not available or not acceptable’) (http://www.
who.int/reproductive-health/publications/mec/mec.pdf). However, we
speculate that this recommendation may be overly cautious and should
be a subject to reconsideration.
Effects of various contraceptives on cervicovaginal shedding of HIV
The circulating HIV load is the most important determinant of cervicova-
ginal shedding of HIV RNA, even among women using antiretroviral medi-
cation (Kovacs et al., 2001; Benki et al., 2004). However, in various studies
occasional cervicovaginal shedding of HIV has been detected in as many as
25–40% of subjects using HAART. As increased genital shedding of HIV
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tive methods on cervicovaginal shedding of HIV is of great interest.
Use of hormonal contraception has been associated with modest
increases in genital shedding of HIV in some (Mostad et al., 1997; Wang
et al., 2004), but not all (Kovacs et al., 2001) studies. However, the clinical
importance, if any, of the slight alterations in cervicovaginal levels of HIV
remains enigmatic.
Besides systemically administered hormonal contraception, the effects
of Cu-IUDs and the LNG-IUS on shedding of HIV has been studied in pro-
spective studies (Richardson et al., 1999; Heikinheimo et al., 2006). Reas-
suringly, use of either a Cu-IUD or the LNG-IUS did not increase cervical
shedding of HIV.
Prevalence of contraceptive use among HIV-infected women
Recent studies have been addressed to the issue of use of contraception
among HIV-infected women in France (Heard et al., 2004), in the USA
(Massad et al., 2007) and among postpartum Kenyan women (Balkus
et al., 2007). The use of effective contraception (sterilization, hormonal
or intrauterine contraception) was low (,30%) both in France and the
USA, whereas high uptake of hormonal contraception (up to 70%) was
reported during the ﬁrst few months after delivery in Kenya.
A quarter of the American women reported the use of sterilization,
whereas hormonal contraception was used by ,10% (Massad et al.,
2007). In the French study, the prevalence of effective contraceptive use
was ,20% (Massad et al., 2007). Serostatus of the partner had a signiﬁ-
cant effect on the contraceptive practices—consistent condom use was
reported during 84% of the visits when the partner was HIV-negative
but only in 57% if the partner was HIV-seropositive (Heard et al.,
2004). However, the prevalence of effective contraceptive use was
higher (31 versus 4%) among seroconcordant couples (Heard et al.,
2004). Thus among serodiscordant couples, minimizing the risk of HIV
transmission by means of condom use was highlighted, whereas in sero-
concordant couples prevention of pregnancy had became more important.
The effect of use of antiretroviral medication on contraceptive practices
has also been assessed. In France, HIV-infected women using HAART
were less likely to use effective contraception (Heard et al., 2004). The
prevalence of effective contraceptive use decreased signiﬁcantly among
serodiscordant couples after the introduction of HAART (Heard et al.,
2004). However, in the USA, use of HAART did not have an effect on
contraceptive practices (Massad et al., 2007). Dual contraception was
used by only a small minority in both studies (Heard et al., 2004;
Massad et al., 2007). Thus, effective contraception remains underused
among HIV-infected women, even those living in developed countries.
Does knowledge of HIV infection alter sexual and contraceptive practices?
As heterosexual intercourse has become the main route of HIV trans-
mission in several parts of the world, lowering the risk via intervention
aimed at reducing risky sexual behaviour has emerged as an important
issue in HIV prevention. In several prospective trials, performed in the
developed world, such interventions have proven successful in promoting
condom use and safe sex (Crepaz et al., 2006). In the only study per-
formed among HIV-infected women, a signiﬁcantly decreased incidence
of STDs and non-use of condoms was seen in the intervention group
(Wingood et al., 2004). Thus behavioural interventions aimed at reducing
risky behaviour can be effective.
How should reproductive health care
services be arranged?
It is clear that contraception, and screening for STDs and pre-malignant
cervical abnormalities are all connected in women living with HIV/AIDS.
Therefore, establishment of services in a manner such that all these
aspects of female reproductive health are covered is important. Guidelines
for organization of such clinics were recently published by the British
Association for Sexual Health and HIV (www.bashh.org). Evaluation of
one such clinic showed that all aspects of sexual health services were
improved following integration of these different aspects of female
health (Coyne et al., 2007).
There will be no single model for arranging reproductive health services
in different areas and countries. In some countries the best way would be
to integrate family planning into public health services; somewhere else a
vertical programme may work more efﬁciently. It will be important to
make both contraception and voluntary HIV counselling and testing
easily accessible and affordable, and preferably free of charge in most
developing countries.
The stigma related to HIV is so strong that it will be an important poten-
tial hindrance to the services unless carefully thought-out. It would make
sense that voluntary counselling and testing for HIV would be provided
together with contraceptive services. However, once HIV infection has
been diagnosed and the treatment provided elsewhere, the staff in the
care unit should also be trained to provide contraceptive services. For
example, it still too often happens that injectables are discontinued
because the services are somewhere else or the day of injection is
overdue.
Future prospects
To provide effective, safe, user-friendly and preferably female-controlled
contraceptive methods, which offer protection from both HIV and unin-
tended pregnancy, is a major biomedical challenge. On that note, one
has to realize that currently, the spread of HIV is both a behavioural
and cultural issue. While condoms provide an effective means of prevent-
ing the spread of HIV, their use remains low in areas where the disease is
most prevalent. Therefore, at a time when new means of HIV prevention
are being developed, a major effort is needed to change attitudes towards
HIV prevention and more stringent adherence to the methods already
available.
Hormonal contraception and HIV infection has been a topic of a major
international meeting in 2005 in Nairobi, Kenya (http://who.int/
reproductive-health/stis/hc_hiv/nairobi_statement.pdf). Besides the
above mentioned WHO endorsed recommendations concerning the
use of contraceptives in women living at the risk of HIV, or with HIV/
AIDS, several recommendations for future research were made. These
included assessment of the effects of hormonal contraception in speciﬁc
subgroups, especially in young women, evaluation of novel contraceptives
(such as vaginal rings and contraceptive patches), further studies on the
effects of contraceptives on the HIV-infection and means to optimize
the use of dual protection.
Contraceptives releasing both antimicrobial and contraceptive mol-
ecules may be one avenue towards a contraceptive microbicide that
potentially could also improve compliance and product adherence
(www.ipm-microbicides.org). Vaginal rings releasing both zidovudine
(AZT) and non-hormonal contraceptive molecules (such as ferrous sul-
phate and ascorbic acid) have been found to be effective in vitro in inhibit-
ing sperm mobility and they released sufﬁcient amounts of AZT to inhibit
HIV proliferation (Han et al., 2007). Similarly, vaginal transmission of HIV
was inhibited by pre-exposure prophylaxis of antiretroviral medication in a
mouse humanized with CD4 lymphocytes (Denton et al., 2008).
Summary
Development and provision of safe, effective, affordable and acceptable
contraception for women at risk of HIV and those living with HIV/AIDS
is one of the major challenges of reproductive medicine. Currently, con-
sistent use of male condoms is the only proven means to reduce the
172 Heikinheimo and La ¨hteenma ¨kirisk of HIV transmission in heterosexual intercourse. All the available
reversible contraceptive methods—OCs, contraceptive injections and
IUDs—can generally be used both by women at risk of HIV infection
and by HIV-infected women. Thus, the current optimal contraceptive
strategy includes dual use of condoms combined with a more effective
contraceptive method. Unfortunately, the reported use of dual contracep-
tion has been very low even in research settings. An ideal contraceptive
strategy for women at risk of HIV infection would provide simultaneous
protection against both unintended pregnancy and HIV acquisition. Appro-
priate products are currently being developed.
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